Free webinar: Novel outpatient COVID treatments
Monday, January 24, 2022
12:00pm - 1:00pm
Previously, monoclonal antibodies (mAb) have been the primary outpatient treatment for high-risk individuals with COVID-19 to reduce hospitalization and severe illness, in addition to vaccines. Only one monoclonal antibody, sotrovimab, is effective against the omicron variant currently circulating, resulting in a shortage of treatments. Fortunately, there are now new promising antiviral treatments including ritonavir boosted nirmatrelvir (Paxlovid) and molnupiravir. However, providers are unfamiliar with these medications, including how to manage drug-drug interactions with Paxlovid and the process for prescribing these medications, which are in short supply. Participants will increase prescribing these novel medications/treatments.